Author in the Room: Antidepressant-Associated Sexual Dysfunction

September 2008 Author in the Room® Teleconference


Author: H. George Numberg, MD


Article: "Sildenafil Treatment of Women with Antidepressant-Associated Sexual Dysfunction: A Randomized Controlled Trial"


Summary Points:

  • Emergent sexual dysfunction (SD) is a principal reason for a three-fold increased risk of non-adherence that leads to increased relapse, recurrence, and poor disease management outcomes.
  • Selective phosphodiesterase-type 5 inhibitors (PDE5Is), limited to studies in men, have demonstrated evidence based data to support broad-based and clinically meaningful treatment efficacy.
  • In an intention-to-treat analysis, women treated with sildenafil showed significant improvement in adverse sexual effects compared with those taking placebo.
  • Evidence shows that selective phosphodiesterase type 5 inhibitors are effective in both sexes for patients who have been effectively treated for depression but need to continue on their medication to avoid relapse or recurrence.
Average Content Rating
(0 user)
Please login to rate or comment on this content.
User Comments